The Australian manufacturing sector is contracting further, as evidenced by the Ai Group Industry Index falling to ...

Yext's bottom line is improving, but organic growth remains challenged. Click here to see why YEXT stock is a Hold.

Kura Oncology's ziftomenib shows promise in AML treatment, with FDA Priority Review ahead. Read here for an analysis of KURA ...